首页 > 最新文献

Therapeutics and Clinical Risk Management最新文献

英文 中文
The Value of Anticoagulation Management Combining Telemedicine and Self-Testing in Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. 远程医疗与自检相结合的抗凝管理在心血管疾病中的价值:一项随机对照试验的meta分析
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S395578
Yu Huang, Yilian Xie, Lei Huang, Zhen Han

Purpose: No consensus has been established on the safety and effectiveness of out-of-hospital management of Vitamin K antagonists (VKA) therapy combining portable coagulometers and telemedicine. The present meta-analysis investigated the safety and effectiveness of this hybrid anticoagulants management model.

Methods: The PubMed, Embase, Cochrane, and Web of Science databases were searched for papers published before May 1, 2022. To reduce bias, only randomized controlled trials were included. RevMan 5.3 (Cochrane) software was used to evaluate and analyze clinical outcomes, including the effectiveness and safety of patient management approaches, determined by the time in the therapeutic range (TTR) and occurrence of thrombotic and bleeding events.

Results: Eight studies, comprising 3853 patients, were selected. The meta-analysis showed that anticoagulant management combining portable coagulometers and telemedicine significantly improved frequency of testing (mean difference [MD]= 12.95 days; 95% CI, 8.77-17.12; I2= 92%; P< 0.01) and TTR (MD= 9.50%; 95% CI, 3.16-15.85; I2= 87%; P< 0.01). Thromboembolism events were reduced (RR= 0.72; 95% CI, 0.51-1.01; I2= 0%; P= 0.05), but the results were not statistically significant. And no significant differences in major bleeding events, rehospitalization rate, mortality, or overall treatment cost existed between the two groups.

Conclusion: Although the safety of remote cardiovascular disease management is not superior to that of conventional outpatient anticoagulant management, it provides a more stable monitoring of coagulation status.

目的:关于维生素K拮抗剂(VKA)联合便携式凝血仪和远程医疗的院外管理的安全性和有效性尚未达成共识。本荟萃分析调查了这种混合抗凝剂管理模式的安全性和有效性。方法:检索PubMed、Embase、Cochrane和Web of Science数据库,检索2022年5月1日之前发表的论文。为减少偏倚,只纳入随机对照试验。使用RevMan 5.3 (Cochrane)软件评估和分析临床结果,包括患者管理方法的有效性和安全性,由治疗范围内时间(TTR)和血栓和出血事件的发生来确定。结果:入选8项研究,共3853例患者。荟萃分析显示,结合便携式凝血仪和远程医疗的抗凝管理显著提高了检测频率(平均差[MD]= 12.95天;95% ci, 8.77-17.12;I2 = 92%;P< 0.01)和TTR (MD= 9.50%;95% ci, 3.16-15.85;I2 = 87%;P < 0.01)。血栓栓塞事件减少(RR= 0.72;95% ci, 0.51-1.01;I2 = 0%;P= 0.05),但结果无统计学意义。两组在大出血事件、再住院率、死亡率或总治疗费用方面无显著差异。结论:虽然心血管疾病远程管理的安全性并不优于常规门诊抗凝管理,但它提供了更稳定的凝血状态监测。
{"title":"The Value of Anticoagulation Management Combining Telemedicine and Self-Testing in Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.","authors":"Yu Huang,&nbsp;Yilian Xie,&nbsp;Lei Huang,&nbsp;Zhen Han","doi":"10.2147/TCRM.S395578","DOIUrl":"https://doi.org/10.2147/TCRM.S395578","url":null,"abstract":"<p><strong>Purpose: </strong>No consensus has been established on the safety and effectiveness of out-of-hospital management of Vitamin K antagonists (VKA) therapy combining portable coagulometers and telemedicine. The present meta-analysis investigated the safety and effectiveness of this hybrid anticoagulants management model.</p><p><strong>Methods: </strong>The PubMed, Embase, Cochrane, and Web of Science databases were searched for papers published before May 1, 2022. To reduce bias, only randomized controlled trials were included. RevMan 5.3 (Cochrane) software was used to evaluate and analyze clinical outcomes, including the effectiveness and safety of patient management approaches, determined by the time in the therapeutic range (TTR) and occurrence of thrombotic and bleeding events.</p><p><strong>Results: </strong>Eight studies, comprising 3853 patients, were selected. The meta-analysis showed that anticoagulant management combining portable coagulometers and telemedicine significantly improved frequency of testing (mean difference [MD]= 12.95 days; 95% CI, 8.77-17.12; I<sup>2</sup>= 92%; P< 0.01) and TTR (MD= 9.50%; 95% CI, 3.16-15.85; I<sup>2</sup>= 87%; P< 0.01). Thromboembolism events were reduced (RR= 0.72; 95% CI, 0.51-1.01; I<sup>2</sup>= 0%; P= 0.05), but the results were not statistically significant. And no significant differences in major bleeding events, rehospitalization rate, mortality, or overall treatment cost existed between the two groups.</p><p><strong>Conclusion: </strong>Although the safety of remote cardiovascular disease management is not superior to that of conventional outpatient anticoagulant management, it provides a more stable monitoring of coagulation status.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/be/tcrm-19-279.PMC10024473.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9156230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. 免疫检查点抑制剂联合瑞非尼作为二线治疗不可切除肝癌患者的临床疗效和安全性
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S400079
Jinpeng Li, Yuntao Jia, Changdong Shao, Yuanming Li, Jinlong Song

Purpose: This study aimed to evaluate the safety and efficacy of a combination of programmed death-1 (PD-1) inhibitor and regorafenib as second-line treatment for advanced hepatocellular carcinoma (HCC).

Patients and methods: We retrospectively analyzed the data of 38 patients with unresectable HCC who were treated with PD-1 inhibitor in combination with regorafenib as a second⁃line therapy as well as the data of 32 patients treated with regorafenib only therapy as a control. The clinical data, previous treatment strategies, follow-up imaging results, and adverse events during follow-ups were recorded. The mRECIST Criteria were used to evaluate the treatment outcome of intrahepatic lesions, and the Kaplan-Meier method was used to evaluate survival time.

Results: Up to the last follow-up, the rego-PD-1 group had higher objective response rate (39.5% vs 15.6%, P = 0.028), longer progression-free survival (median 5.9 vs 4.6 months; P = 0.044), and better overall survival (OS) (median 14.5 vs 9.5 months; P = 0.041) than the regorafenib only group. Among the 38 patients in rego-PD-1 group, 1 patient (2.7%) achieved complete response, 14 patients (36.8%) achieved partial response, 14 patients (36.8%) achieved stable disease, and 9 patients (23.7%) achieved progressive disease. Among the 32 patients in regorafenib alone, 5 (15.6%) achieved partial response, 12 (37.5%) achieved stable disease, and 15 (46.9%) achieved progressive disease. Regorafenib alone, Child-Pugh B, and tumors >3 were independent prognostic factors for poor OS. The difference in the incidence of grade 3/4 adverse events between the two groups was not statistically significant (36.8% vs 28.1%; P = 0.439). Grade ≥3 treatment-related adverse events included hypertension and diarrhea.

Conclusion: PD-1 inhibitor combined with regorafenib is a promising regimen in treating patients with unresectable HCC owing to its safety and effectiveness as well as low incidence of serious adverse events with its use.

目的:本研究旨在评估程序性死亡-1 (PD-1)抑制剂联合瑞戈非尼作为晚期肝细胞癌(HCC)二线治疗的安全性和有效性。患者和方法:我们回顾性分析了38例不可切除HCC患者的数据,这些患者接受PD-1抑制剂联合瑞哥非尼作为二线治疗,以及32例仅接受瑞哥非尼作为对照的患者的数据。记录临床资料、既往治疗策略、随访影像结果及随访期间不良事件。采用mRECIST标准评价肝内病变的治疗效果,Kaplan-Meier法评价生存时间。结果:截至最后一次随访,雷戈- pd -1组客观缓解率更高(39.5% vs 15.6%, P = 0.028),无进展生存期更长(中位5.9 vs 4.6个月;P = 0.044)和更好的总生存期(OS)(中位14.5 vs 9.5个月;P = 0.041)。rego-PD-1组38例患者中,完全缓解1例(2.7%),部分缓解14例(36.8%),病情稳定14例(36.8%),病情进展9例(23.7%)。在单独使用瑞非尼的32例患者中,5例(15.6%)达到部分缓解,12例(37.5%)达到疾病稳定,15例(46.9%)达到疾病进展。单独瑞非尼、Child-Pugh B和肿瘤>3是不良OS的独立预后因素。两组患者3/4级不良事件发生率差异无统计学意义(36.8% vs 28.1%;P = 0.439)。≥3级治疗相关不良事件包括高血压和腹泻。结论:PD-1抑制剂联合瑞非尼治疗不可切除HCC安全有效,严重不良事件发生率低,是一种有前景的治疗方案。
{"title":"Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.","authors":"Jinpeng Li,&nbsp;Yuntao Jia,&nbsp;Changdong Shao,&nbsp;Yuanming Li,&nbsp;Jinlong Song","doi":"10.2147/TCRM.S400079","DOIUrl":"https://doi.org/10.2147/TCRM.S400079","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the safety and efficacy of a combination of programmed death-1 (PD-1) inhibitor and regorafenib as second-line treatment for advanced hepatocellular carcinoma (HCC).</p><p><strong>Patients and methods: </strong>We retrospectively analyzed the data of 38 patients with unresectable HCC who were treated with PD-1 inhibitor in combination with regorafenib as a second⁃line therapy as well as the data of 32 patients treated with regorafenib only therapy as a control. The clinical data, previous treatment strategies, follow-up imaging results, and adverse events during follow-ups were recorded. The mRECIST Criteria were used to evaluate the treatment outcome of intrahepatic lesions, and the Kaplan-Meier method was used to evaluate survival time.</p><p><strong>Results: </strong>Up to the last follow-up, the rego-PD-1 group had higher objective response rate (39.5% vs 15.6%, P = 0.028), longer progression-free survival (median 5.9 vs 4.6 months; P = 0.044), and better overall survival (OS) (median 14.5 vs 9.5 months; P = 0.041) than the regorafenib only group. Among the 38 patients in rego-PD-1 group, 1 patient (2.7%) achieved complete response, 14 patients (36.8%) achieved partial response, 14 patients (36.8%) achieved stable disease, and 9 patients (23.7%) achieved progressive disease. Among the 32 patients in regorafenib alone, 5 (15.6%) achieved partial response, 12 (37.5%) achieved stable disease, and 15 (46.9%) achieved progressive disease. Regorafenib alone, Child-Pugh B, and tumors >3 were independent prognostic factors for poor OS. The difference in the incidence of grade 3/4 adverse events between the two groups was not statistically significant (36.8% vs 28.1%; P = 0.439). Grade ≥3 treatment-related adverse events included hypertension and diarrhea.</p><p><strong>Conclusion: </strong>PD-1 inhibitor combined with regorafenib is a promising regimen in treating patients with unresectable HCC owing to its safety and effectiveness as well as low incidence of serious adverse events with its use.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/ce/tcrm-19-329.PMC10083010.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9290092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Efficacy of Herbs as Complementary and Alternative Therapy in Recovery and Clinical Outcome Among People with COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression. 草药作为补充和替代疗法对COVID-19患者康复和临床结果的疗效:系统评价、荟萃分析和荟萃回归
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S405507
Maria Komariah, Shakira Amirah, Sidik Maulana, Muhammad Fahd Abdurrahman, Kusman Ibrahim, Hesti Platini, Juan Alessandro Jeremis Maruli Nura Lele, Kelvin Kohar, Laili Rahayuwati, Mohd Khairul Zul Hasymi Firdaus

Background: The COVID-19 pandemic continues, and this condition has caused many cases in various countries around the world, resulting in more than 6 million deaths worldwide. Herbal medicines can act as immunomodulators, anti-inflammatories, antioxidants, antimicrobials, and others depending on the type and content of the herbs used. Previous studies have shown that several types of herbs, such as Echinacea purpurea, Curcumin or Turmeric, Nigella sativa, and Zingiber officinale, have proven their effectiveness as herbal plants for COVID-19.

Methods: We conducted a comprehensive literature search through five databases, namely, PubMed, Scopus, Embase, Wiley, and ProQuest to assess the efficacy of phytopharmaceuticals until July 12, 2022. We used the Cochrane RoB 2.0 for the quality assessment of the study.

Results: Phytopharmaceuticals significantly improved patients' recovery rate (OR = 3.54; p < 0.00001) and reduced deaths (OR = 0.24; p < 0.0001) compared to the control group. Phytopharmaceuticals also performed as a protective factor for COVID-19 clinical symptoms, such as dyspnea (OR = 0.42; p < 0.05) and myalgia (OR = 0.31; p = 0.02) compared to the control group. However, there is no statistically significant effect on cough (OR = 0.76; p = 0.61) and fever (OR = 0.60; p < 0.20). The results were not affected by patients' covariates [hypertension, diabetes mellitus, and cardiovascular diseases (meta-regression p > 0.05)].

Conclusion: Herbal medicine has the potential as an adjuvant therapy in the management of COVID-19.

背景:COVID-19大流行仍在继续,这种情况在世界各国造成了许多病例,导致全球600多万人死亡。草药可以作为免疫调节剂、抗炎药、抗氧化剂、抗菌剂和其他取决于草药的类型和含量。之前的研究表明,紫锥菊、姜黄素或姜黄、黑草和生姜等几种草药已被证明是治疗COVID-19的有效草药。方法:截至2022年7月12日,我们通过PubMed、Scopus、Embase、Wiley、ProQuest等5个数据库进行了全面的文献检索,评估植物药的疗效。我们使用Cochrane RoB 2.0对研究进行质量评估。结果:植物药显著提高患者治愈率(OR = 3.54;p < 0.00001),死亡率降低(OR = 0.24;P < 0.0001)。植物药也是COVID-19临床症状的保护因素,如呼吸困难(OR = 0.42;p < 0.05)和肌痛(OR = 0.31;P = 0.02)。但对咳嗽无统计学意义(OR = 0.76;p = 0.61)和发热(OR = 0.60;P < 0.20)。结果不受患者协变量[高血压、糖尿病、心血管疾病]的影响(meta-regression p > 0.05)。结论:中药作为新型冠状病毒肺炎的辅助治疗手段具有一定的潜力。
{"title":"The Efficacy of Herbs as Complementary and Alternative Therapy in Recovery and Clinical Outcome Among People with COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression.","authors":"Maria Komariah,&nbsp;Shakira Amirah,&nbsp;Sidik Maulana,&nbsp;Muhammad Fahd Abdurrahman,&nbsp;Kusman Ibrahim,&nbsp;Hesti Platini,&nbsp;Juan Alessandro Jeremis Maruli Nura Lele,&nbsp;Kelvin Kohar,&nbsp;Laili Rahayuwati,&nbsp;Mohd Khairul Zul Hasymi Firdaus","doi":"10.2147/TCRM.S405507","DOIUrl":"https://doi.org/10.2147/TCRM.S405507","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic continues, and this condition has caused many cases in various countries around the world, resulting in more than 6 million deaths worldwide. Herbal medicines can act as immunomodulators, anti-inflammatories, antioxidants, antimicrobials, and others depending on the type and content of the herbs used. Previous studies have shown that several types of herbs, such as <i>Echinacea purpurea, Curcumin or Turmeric, Nigella sativa, and Zingiber officinale</i>, have proven their effectiveness as herbal plants for COVID-19.</p><p><strong>Methods: </strong>We conducted a comprehensive literature search through five databases, namely, PubMed, Scopus, Embase, Wiley, and ProQuest to assess the efficacy of phytopharmaceuticals until July 12, 2022. We used the Cochrane RoB 2.0 for the quality assessment of the study.</p><p><strong>Results: </strong>Phytopharmaceuticals significantly improved patients' recovery rate (OR = 3.54; <i>p</i> < 0.00001) and reduced deaths (OR = 0.24; <i>p</i> < 0.0001) compared to the control group. Phytopharmaceuticals also performed as a protective factor for COVID-19 clinical symptoms, such as dyspnea (OR = 0.42; <i>p</i> < 0.05) and myalgia (OR = 0.31; <i>p</i> = 0.02) compared to the control group. However, there is no statistically significant effect on cough (OR = 0.76; <i>p</i> = 0.61) and fever (OR = 0.60; <i>p</i> < 0.20). The results were not affected by patients' covariates [hypertension, diabetes mellitus, and cardiovascular diseases (meta-regression <i>p</i> > 0.05)].</p><p><strong>Conclusion: </strong>Herbal medicine has the potential as an adjuvant therapy in the management of COVID-19.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/8e/tcrm-19-611.PMC10362865.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9867117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Intraoperative Variables Enhance the Predictive Performance of Myocardial Injury in Patients with High Cardiovascular Risk After Thoracic Surgery When Added to Baseline Prediction Model. 在基线预测模型中加入术中变量可提高胸外科术后高危心血管患者心肌损伤的预测效果
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S408135
Shuchi Lin, Xiaofan Huang, Ying Zhang, Xiaohan Zhang, Erhong Cheng, Jindong Liu

Purpose: Myocardial injury after non-cardiac surgery is closely related to major adverse cardiac and cerebrovascular event and is difficult to identify. This study aims to investigate how to predict the myocardial injury of thoracic surgery and whether intraoperative variables contribute to the prediction of myocardial injury.

Methods: The prospective study included adult patients with high cardiovascular risk who underwent elective thoracic surgery from May 2022 to October 2022. Multivariate logistic regression was used to establish a model with baseline variables and a model with baseline and intraoperative variables. We compare the predictive performance of two models for postoperative myocardial injury.

Results: In general, 31.5% (94 of 298) occurred myocardial injury. Age ≥65 years old, obesity, smoking, preoperative hsTnT, and one-lung ventilation time were independent predictors of myocardial injury. Compared with baseline model, the intraoperative variables improved model fit, modestly improved the reclassification (continuous net reclassification improvement 0.409, 95% CI, 0.169 to 0.648, P<0.001, improved integrated discrimination 0.036, 95% CI, 0.011 to 0.062, P<0.01) of myocardial injury cases, and achieved higher net benefit in decision curve analysis.

Conclusion: The risk stratification and anesthesia management of high-risk patients are essential. The addition of intraoperative variables to the baseline predictive model improved the performance of the overall model of myocardial injury and helped anesthesiologists screen out the patients at the greatest risk for myocardial injury and adjust anesthesia strategies.

目的:非心脏手术后心肌损伤与重大心脑血管不良事件密切相关,且难以识别。本研究旨在探讨如何预测胸外科手术心肌损伤,以及术中变量是否有助于预测心肌损伤。方法:前瞻性研究纳入2022年5月至2022年10月接受择期胸外科手术的心血管高危成人患者。采用多因素logistic回归建立基线变量模型和基线及术中变量模型。我们比较了两种模型对术后心肌损伤的预测性能。结果:298例患者中有94例(31.5%)发生心肌损伤。年龄≥65岁、肥胖、吸烟、术前hsTnT和单肺通气时间是心肌损伤的独立预测因素。与基线模型相比,术中变量改善了模型拟合,适度改善了重分类(连续净重分类改善0.409,95% CI, 0.169 ~ 0.648, ppp)。结论:高危患者的风险分层和麻醉管理至关重要。在基线预测模型中加入术中变量,提高了心肌损伤整体模型的性能,有助于麻醉医师筛选出心肌损伤风险最大的患者,调整麻醉策略。
{"title":"Intraoperative Variables Enhance the Predictive Performance of Myocardial Injury in Patients with High Cardiovascular Risk After Thoracic Surgery When Added to Baseline Prediction Model.","authors":"Shuchi Lin,&nbsp;Xiaofan Huang,&nbsp;Ying Zhang,&nbsp;Xiaohan Zhang,&nbsp;Erhong Cheng,&nbsp;Jindong Liu","doi":"10.2147/TCRM.S408135","DOIUrl":"https://doi.org/10.2147/TCRM.S408135","url":null,"abstract":"<p><strong>Purpose: </strong>Myocardial injury after non-cardiac surgery is closely related to major adverse cardiac and cerebrovascular event and is difficult to identify. This study aims to investigate how to predict the myocardial injury of thoracic surgery and whether intraoperative variables contribute to the prediction of myocardial injury.</p><p><strong>Methods: </strong>The prospective study included adult patients with high cardiovascular risk who underwent elective thoracic surgery from May 2022 to October 2022. Multivariate logistic regression was used to establish a model with baseline variables and a model with baseline and intraoperative variables. We compare the predictive performance of two models for postoperative myocardial injury.</p><p><strong>Results: </strong>In general, 31.5% (94 of 298) occurred myocardial injury. Age ≥65 years old, obesity, smoking, preoperative hsTnT, and one-lung ventilation time were independent predictors of myocardial injury. Compared with baseline model, the intraoperative variables improved model fit, modestly improved the reclassification (continuous net reclassification improvement 0.409, 95% CI, 0.169 to 0.648, <i>P</i><0.001, improved integrated discrimination 0.036, 95% CI, 0.011 to 0.062, <i>P</i><0.01) of myocardial injury cases, and achieved higher net benefit in decision curve analysis.</p><p><strong>Conclusion: </strong>The risk stratification and anesthesia management of high-risk patients are essential. The addition of intraoperative variables to the baseline predictive model improved the performance of the overall model of myocardial injury and helped anesthesiologists screen out the patients at the greatest risk for myocardial injury and adjust anesthesia strategies.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b0/79/tcrm-19-435.PMC10225131.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasonographic Assessment of Gastric Volume in Fasted Patients Undergoing Gastrointestinal Endoscopy Under Sedation. 镇静下禁食胃肠内镜检查患者胃容量的超声评估。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S424890
Heng Rong, Weixin Dai, Yinying Qin, Zhikeng Meng, Xia Zou, Binbin Wang, Qiufeng Wei, Yubo Xie

Purpose: In this prospective observational study, an ultrasonographic measurement of antral cross-sectional area (ACSA) was conducted to evaluate the gastric content and volume as well as to identify high-risk stomach in non-pregnant adult surgical patients adhering to preanesthetic fasting guidelines.

Patients and methods: Fasted patients undergoing gastrointestinal endoscopy under sedation were included. Ultrasonographic measurements of ACSA were conducted in both semi-recumbent and right lateral decubitus positions before endoscopic procedures. Gastroscopy was employed to guide the measurement of suctioned gastric volume (GV). Ultrasonography was performed to assess gastric contents and identify patients with high-risk stomach. The relationship between ACSA and suctioned GV was also evaluated.

Results: ACSA was evaluated in 736 out of 782 patients. A significant positive correlation was discovered between ACSA in the right lateral decubitus position and suctioned GV, which was more reliable than in the semi-recumbent position. To analyze high-risk stomach with a GV > 100 mL, the cutoff value of ACSA in the right lateral decubitus was found to be 7.5 cm2, with the AUC, sensitivity and specificity of 0.80 (95% CI, 0.76-0.82; P<0.001), 82.4% and 67.3%, respectively. A novel mathematical model based on ACSA to estimate GV in non-pregnant fasted adults was presented.

Conclusion: Ultrasonographic measurement of ACSA can assist anesthesiologists in estimating the risk of pulmonary aspiration of gastric contents during general anesthesia and sedation.

目的:在这项前瞻性观察研究中,通过超声测量胃窦横断面积(ACSA)来评估非妊娠成人手术患者遵守麻醉前禁食指南的胃内容物和胃容量,并识别高危胃。患者和方法:纳入镇静下禁食的胃肠内镜检查患者。超声测量ACSA在半卧位和右侧卧位进行内镜手术前。采用胃镜指导吸胃容积(GV)的测量。超声检查评估胃内容物,识别高危胃患者。并评价了ACSA与抽吸GV的关系。结果:782例患者中有736例进行了ACSA评估。右侧侧卧位的ACSA与抽吸的GV呈显著正相关,比半卧位更可靠。分析GV > 100 mL的高危胃,发现右侧卧位ACSA的临界值为7.5 cm2, AUC、敏感性和特异性为0.80 (95% CI, 0.76-0.82;结论:超声测量ACSA可帮助麻醉医师评估全麻及镇静时肺误吸胃内容物的风险。
{"title":"Ultrasonographic Assessment of Gastric Volume in Fasted Patients Undergoing Gastrointestinal Endoscopy Under Sedation.","authors":"Heng Rong,&nbsp;Weixin Dai,&nbsp;Yinying Qin,&nbsp;Zhikeng Meng,&nbsp;Xia Zou,&nbsp;Binbin Wang,&nbsp;Qiufeng Wei,&nbsp;Yubo Xie","doi":"10.2147/TCRM.S424890","DOIUrl":"https://doi.org/10.2147/TCRM.S424890","url":null,"abstract":"<p><strong>Purpose: </strong>In this prospective observational study, an ultrasonographic measurement of antral cross-sectional area (ACSA) was conducted to evaluate the gastric content and volume as well as to identify high-risk stomach in non-pregnant adult surgical patients adhering to preanesthetic fasting guidelines.</p><p><strong>Patients and methods: </strong>Fasted patients undergoing gastrointestinal endoscopy under sedation were included. Ultrasonographic measurements of ACSA were conducted in both semi-recumbent and right lateral decubitus positions before endoscopic procedures. Gastroscopy was employed to guide the measurement of suctioned gastric volume (GV). Ultrasonography was performed to assess gastric contents and identify patients with high-risk stomach. The relationship between ACSA and suctioned GV was also evaluated.</p><p><strong>Results: </strong>ACSA was evaluated in 736 out of 782 patients. A significant positive correlation was discovered between ACSA in the right lateral decubitus position and suctioned GV, which was more reliable than in the semi-recumbent position. To analyze high-risk stomach with a GV > 100 mL, the cutoff value of ACSA in the right lateral decubitus was found to be 7.5 cm<sup>2</sup>, with the AUC, sensitivity and specificity of 0.80 (95% CI, 0.76-0.82; P<0.001), 82.4% and 67.3%, respectively. A novel mathematical model based on ACSA to estimate GV in non-pregnant fasted adults was presented.</p><p><strong>Conclusion: </strong>Ultrasonographic measurement of ACSA can assist anesthesiologists in estimating the risk of pulmonary aspiration of gastric contents during general anesthesia and sedation.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/1d/tcrm-19-685.PMC10460589.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10484901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to Continuous Positive Airway Pressure Therapy in Pediatric Patients with Obstructive Sleep Apnea: A Meta-Analysis. 阻塞性睡眠呼吸暂停患儿坚持持续气道正压治疗:一项荟萃分析。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S358737
Bundit Sawunyavisuth, Chetta Ngamjarus, Kittisak Sawanyawisuth

Introduction: Obstructive sleep apnea (OSA) is a public health problem that affects children. Although continuous positive airway pressure (CPAP) therapy is effective, the CPAP adherence rate in children is varied. This study aimed to evaluate the CPAP adherence rate and factors associated with CPAP adherence in children with OSA using a systematic review.

Methods: The inclusion criteria were observational studies conducted in children with OSA and assessed adherence of CPAP using objective evaluation. The literature search was performed in four databases. Meta-analysis using fixed-effect model was conducted to combine results among included studies.

Results: In all, 34 studies that evaluated adherence rate and predictors of CPAP adherence in children with OSA were included, representing 21,737 patients with an average adherence rate of 46.56%. There were 11 calculations of factors predictive of CPAP adherence: age, sex, ethnicity, body mass index, obesity, income, sleep efficiency, the apnea-hypopnea index (AHI), severity of OSA, residual AHI, and lowest oxygen saturation level. Three different factors were linked to children with adherence and non-adherence to CPAP: age, body mass index, and AHI.

Conclusion: The CPAP adherence rate in children with OSA was 46.56%. Young age, low body mass index, and high AHI were associated with acceptable CPAP adherence in children with OSA.

梗阻性睡眠呼吸暂停(OSA)是影响儿童的公共卫生问题。虽然持续气道正压(CPAP)治疗是有效的,但儿童的CPAP依从率各不相同。本研究旨在通过系统回顾评估阻塞性睡眠呼吸暂停(OSA)患儿的CPAP依从率和与CPAP依从性相关的因素。方法:纳入标准为对OSA患儿进行观察性研究,采用客观评价法评估CPAP的依从性。在四个数据库中进行文献检索。采用固定效应模型进行meta分析,将纳入研究的结果合并。结果:总共纳入34项评估OSA患儿CPAP依从率和预测因素的研究,共21737例患者,平均依从率为46.56%。有11个预测CPAP依从性的因素计算:年龄、性别、种族、体重指数、肥胖、收入、睡眠效率、呼吸暂停低通气指数(AHI)、OSA严重程度、残留AHI和最低血氧饱和度。三个不同的因素与坚持和不坚持CPAP的儿童有关:年龄、体重指数和AHI。结论:OSA患儿CPAP依从率为46.56%。年龄小、低体重指数和高AHI与OSA患儿可接受的CPAP依从性相关。
{"title":"Adherence to Continuous Positive Airway Pressure Therapy in Pediatric Patients with Obstructive Sleep Apnea: A Meta-Analysis.","authors":"Bundit Sawunyavisuth,&nbsp;Chetta Ngamjarus,&nbsp;Kittisak Sawanyawisuth","doi":"10.2147/TCRM.S358737","DOIUrl":"https://doi.org/10.2147/TCRM.S358737","url":null,"abstract":"<p><strong>Introduction: </strong>Obstructive sleep apnea (OSA) is a public health problem that affects children. Although continuous positive airway pressure (CPAP) therapy is effective, the CPAP adherence rate in children is varied. This study aimed to evaluate the CPAP adherence rate and factors associated with CPAP adherence in children with OSA using a systematic review.</p><p><strong>Methods: </strong>The inclusion criteria were observational studies conducted in children with OSA and assessed adherence of CPAP using objective evaluation. The literature search was performed in four databases. Meta-analysis using fixed-effect model was conducted to combine results among included studies.</p><p><strong>Results: </strong>In all, 34 studies that evaluated adherence rate and predictors of CPAP adherence in children with OSA were included, representing 21,737 patients with an average adherence rate of 46.56%. There were 11 calculations of factors predictive of CPAP adherence: age, sex, ethnicity, body mass index, obesity, income, sleep efficiency, the apnea-hypopnea index (AHI), severity of OSA, residual AHI, and lowest oxygen saturation level. Three different factors were linked to children with adherence and non-adherence to CPAP: age, body mass index, and AHI.</p><p><strong>Conclusion: </strong>The CPAP adherence rate in children with OSA was 46.56%. Young age, low body mass index, and high AHI were associated with acceptable CPAP adherence in children with OSA.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/2d/tcrm-19-143.PMC9904217.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Comparative Effectiveness of MRI, 4D-CT and Ultrasonography in Patients with Secondary Hyperparathyroidism. MRI、4D-CT及超声对继发性甲状旁腺功能亢进的疗效比较。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S379814
Jiaoping Mi, Yijie Fang, Jianzhong Xian, Guojie Wang, Yuanqing Guo, Haiyu Hong, Mengshi Chi, Yong-Fang Li, Peng He, Jiebing Gao, Wei Liao

Objective: Accurate preoperative localization of abnormal parathyroid glands is crucial for successful surgical management of secondary hyperparathyroidism (SHPT). This study was conducted to compare the effectiveness of preoperative MRI, 4D-CT, and ultrasonography (US) in localizing parathyroid lesions in patients with SHPT.

Methods: We performed a retrospective review of prospectively collected data from a tertiary-care hospital and identified 52 patients who received preoperative MRI and/or 4D-CT and/or US and/or 99mTc-MIBI and subsequently underwent surgery for SHPT between May 2013 and March 2020. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of each imaging modality to accurately detect enlarged parathyroid glands were determined using histopathology as the criterion standard with confirmation using the postoperative biochemical response.

Results: A total of 198 lesions were identified intraoperatively among the 52 patients included in this investigation. MRI outperformed 4D-CT and US in terms of sensitivity (P < 0.01), specificity (P = 0.455), PPV (P = 0.753), and NPV (P = 0.185). The sensitivity and specificity for MRI, 4D-CT, and US were 90.91%, 88.95%, and 66.23% and 58.33%, 63.64%, and 50.00%, respectively. The PPV of combined MRI and 4D-CT (96.52%) was the highest among the combined 2 modalities. The smallest diameter of the parathyroid gland precisely localized by MRI was 8×3 mm, 5×5 mm by 4D-CT, and 5×3 mm by US.

Conclusion: MRI has superior diagnostic performance compared with other modalities as a first-line imaging study for patients undergoing renal hyperparathyroidism, especially for ectopic or small parathyroid lesions. We suggest performing US first for diagnosis and then MRI to make a precise localization, and MRI proved to be very helpful in achieving a high success rate in the surgical treatment of renal hyperparathyroidism in our own experience.

目的:术前准确定位异常甲状旁腺是继发性甲状旁腺功能亢进(SHPT)手术治疗成功的关键。本研究旨在比较术前MRI、4D-CT和超声(US)对SHPT患者甲状旁腺病变定位的有效性。方法:我们对一家三级医院前瞻性收集的数据进行了回顾性分析,并确定了2013年5月至2020年3月期间接受术前MRI和/或4D-CT和/或US和/或99mTc-MIBI并随后接受SHPT手术的52例患者。以组织病理学为标准确定各成像方式准确检测甲状旁腺肿大的敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV),并用术后生化反应进行确认。结果:52例患者术中共发现198个病变。MRI在敏感性(P < 0.01)、特异性(P = 0.455)、PPV (P = 0.753)和NPV (P = 0.185)方面优于4D-CT和US。MRI、4D-CT、US的敏感性、特异性分别为90.91%、88.95%、66.23%、58.33%、63.64%、50.00%。MRI和4D-CT联合检查的PPV最高,为96.52%。MRI精确定位的甲状旁腺最小直径为8×3 mm, 4D-CT为5×5 mm, US为5×3 mm。结论:对于肾性甲状旁腺功能亢进患者,尤其是异位或小的甲状旁腺病变,MRI作为一线影像学检查具有优越的诊断价值。我们建议先做US诊断,再做MRI精确定位,根据我们的经验,MRI对肾性甲状旁腺功能亢进的手术治疗成功率很高。
{"title":"Comparative Effectiveness of MRI, 4D-CT and Ultrasonography in Patients with Secondary Hyperparathyroidism.","authors":"Jiaoping Mi,&nbsp;Yijie Fang,&nbsp;Jianzhong Xian,&nbsp;Guojie Wang,&nbsp;Yuanqing Guo,&nbsp;Haiyu Hong,&nbsp;Mengshi Chi,&nbsp;Yong-Fang Li,&nbsp;Peng He,&nbsp;Jiebing Gao,&nbsp;Wei Liao","doi":"10.2147/TCRM.S379814","DOIUrl":"https://doi.org/10.2147/TCRM.S379814","url":null,"abstract":"<p><strong>Objective: </strong>Accurate preoperative localization of abnormal parathyroid glands is crucial for successful surgical management of secondary hyperparathyroidism (SHPT). This study was conducted to compare the effectiveness of preoperative MRI, 4D-CT, and ultrasonography (US) in localizing parathyroid lesions in patients with SHPT.</p><p><strong>Methods: </strong>We performed a retrospective review of prospectively collected data from a tertiary-care hospital and identified 52 patients who received preoperative MRI and/or 4D-CT and/or US and/or <sup>99m</sup>Tc-MIBI and subsequently underwent surgery for SHPT between May 2013 and March 2020. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of each imaging modality to accurately detect enlarged parathyroid glands were determined using histopathology as the criterion standard with confirmation using the postoperative biochemical response.</p><p><strong>Results: </strong>A total of 198 lesions were identified intraoperatively among the 52 patients included in this investigation. MRI outperformed 4D-CT and US in terms of sensitivity (P < 0.01), specificity (P = 0.455), PPV (P = 0.753), and NPV (P = 0.185). The sensitivity and specificity for MRI, 4D-CT, and US were 90.91%, 88.95%, and 66.23% and 58.33%, 63.64%, and 50.00%, respectively. The PPV of combined MRI and 4D-CT (96.52%) was the highest among the combined 2 modalities. The smallest diameter of the parathyroid gland precisely localized by MRI was 8×3 mm, 5×5 mm by 4D-CT, and 5×3 mm by US.</p><p><strong>Conclusion: </strong>MRI has superior diagnostic performance compared with other modalities as a first-line imaging study for patients undergoing renal hyperparathyroidism, especially for ectopic or small parathyroid lesions. We suggest performing US first for diagnosis and then MRI to make a precise localization, and MRI proved to be very helpful in achieving a high success rate in the surgical treatment of renal hyperparathyroidism in our own experience.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/93/tcrm-19-369.PMC10163888.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9444306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Individualized Red Blood Cell Transfusion Strategy Using Pediatric Perioperative-Transfusion-Trigger Score Reduced Perioperative Blood Exposure for Children: A Randomized Controlled Clinical Trial. 使用儿科围手术期输血触发评分降低儿童围手术期血液暴露的个体化红细胞输血策略:一项随机对照临床试验。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S388924
Zhen Luo, Yansong Li, Xiaoqiang Li, Ren Liao

Objective: The optimal red blood cell transfusion strategy for children remains unclear. We developed an individualized red blood cell transfusion strategy for children and tested the hypothesis that transfusion guided by this strategy could reduce blood exposure, without increasing perioperative complications in children.

Methods: In this randomized controlled clinical trial, 99 children undergoing noncardiac surgeries who had blood loss of more than 20% total blood volume were randomly assigned to an individualized-strategy group using Pediatric Perioperative-Transfusion-Trigger Score or a control group. The amount of transfused red blood cell was counted, and patients were followed up for postoperative complications within 30 days.

Results: Twenty-six children (53.1%) in the individualized-strategy group received transfusion perioperatively, as compared with 37 children (74%) in the control group (p < 0.05). During surgery, children in the individualized-strategy group were exposed to fewer transfusions than in the control group (0.87±1.03 vs 1.33±1.20 Red-Blood-Cell units per patient, p = 0.02). The incidence of severe complications in the individualized-strategy group had a lower trend compared to the control group (8.2% vs 18%, p = 0.160). No significant difference was found in the other outcomes.

Conclusion: This trial proved that red blood cell transfusion guided by the individualized strategy reduced perioperative blood exposure in children, without increasing the incidence of severe complications. This conclusion needs to be reaffirmed by larger-scale, multicenter clinical trials.

目的:儿童红细胞输注的最佳策略尚不清楚。我们为儿童开发了一种个性化的红细胞输血策略,并验证了这样一种假设,即在这种策略指导下输血可以减少血液暴露,而不会增加儿童围手术期并发症。方法:在这项随机对照临床试验中,99名接受非心脏手术的失血量超过总血容量20%的儿童被随机分配到使用儿科围手术期输血触发评分的个性化策略组或对照组。统计输注红细胞量,30 d内随访患者术后并发症情况。结果:个体化策略组围术期输血患儿26例(53.1%),对照组37例(74%)(p < 0.05)。手术期间,个体化策略组患儿输血量低于对照组(0.87±1.03 vs 1.33±1.20红细胞单位/例,p = 0.02)。与对照组相比,个体化治疗组的严重并发症发生率有较低的趋势(8.2% vs 18%, p = 0.160)。其他结果无显著差异。结论:本试验证明个体化策略指导下的红细胞输血可减少患儿围手术期血液暴露,且不增加严重并发症的发生率。这一结论需要通过更大规模的多中心临床试验来确认。
{"title":"An Individualized Red Blood Cell Transfusion Strategy Using Pediatric Perioperative-Transfusion-Trigger Score Reduced Perioperative Blood Exposure for Children: A Randomized Controlled Clinical Trial.","authors":"Zhen Luo,&nbsp;Yansong Li,&nbsp;Xiaoqiang Li,&nbsp;Ren Liao","doi":"10.2147/TCRM.S388924","DOIUrl":"https://doi.org/10.2147/TCRM.S388924","url":null,"abstract":"<p><strong>Objective: </strong>The optimal red blood cell transfusion strategy for children remains unclear. We developed an individualized red blood cell transfusion strategy for children and tested the hypothesis that transfusion guided by this strategy could reduce blood exposure, without increasing perioperative complications in children.</p><p><strong>Methods: </strong>In this randomized controlled clinical trial, 99 children undergoing noncardiac surgeries who had blood loss of more than 20% total blood volume were randomly assigned to an individualized-strategy group using Pediatric Perioperative-Transfusion-Trigger Score or a control group. The amount of transfused red blood cell was counted, and patients were followed up for postoperative complications within 30 days.</p><p><strong>Results: </strong>Twenty-six children (53.1%) in the individualized-strategy group received transfusion perioperatively, as compared with 37 children (74%) in the control group (p < 0.05). During surgery, children in the individualized-strategy group were exposed to fewer transfusions than in the control group (0.87±1.03 vs 1.33±1.20 Red-Blood-Cell units per patient, p = 0.02). The incidence of severe complications in the individualized-strategy group had a lower trend compared to the control group (8.2% vs 18%, p = 0.160). No significant difference was found in the other outcomes.</p><p><strong>Conclusion: </strong>This trial proved that red blood cell transfusion guided by the individualized strategy reduced perioperative blood exposure in children, without increasing the incidence of severe complications. This conclusion needs to be reaffirmed by larger-scale, multicenter clinical trials.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/7d/tcrm-19-229.PMC10015971.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9143063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA). 多药治疗和衰老对接受泛型直接作用抗病毒药物(pDAA)治疗的HCV患者多重药物-药物相互作用(ddi)风险影响的意大利真实世界分析
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S394467
Stefano Fagiuoli, Pierluigi Toniutto, Nicola Coppola, Domenica Daniela Ancona, Margherita Andretta, Fausto Bartolini, Fulvio Ferrante, Alessandro Lupi, Stefano Palcic, Francesca Vittoria Rizzi, Davide Re, Gema Alvarez Nieto, Candido Hernandez, Francesca Frigerio, Valentina Perrone, Luca Degli Esposti, Alessandra Mangia

Purpose: The study aims at investigating the impact of polymedication and aging in the prevalence of multiple drug-drug interactions (DDIs) on HCV patients treated with sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).

Patients and methods: This is a retrospective analysis based on administrative data covering around 6.9 million individuals. Patients treated with SOF/VEL or GLE/PIB over November 2017-March 2020 were included. Index date corresponded to SOF/VEL or GLE/PIB first prescription during such period; patients were followed up for treatment duration. Analyses were then focused on patients with ≥2 comedications at risk of multiple DDIs. The severity and the effect of multiple DDI were identified using the Liverpool University tool.

Results: A total of 2057 patients with SOF/VEL and 2128 with GLE/PIB were selected. Mean age of SOF/VEL patients was 58.5 years, higher than GLE/PIB ones (52.5 years) (p < 0.001), and patients >50 years were more present in SOF/VEL vs GLE/PIB cohorts: 72% vs 58%, (p < 0.001). Most prescribed co-medications were cardiovascular, alimentary and nervous system drugs. Proportion of patients with ≥2 comedications was higher in SOF/VEL compared to GLE/PIB cohort (56.5% vs 32.3%, p < 0.001). Those at high-risk of multiple DDIs accounted for 11.6% (N = 135) of SOF/VEL and 19.6% (N = 135) of GLE/PIB (p < 0.001) patients with ≥2 comedications. Among them, the potential effect of DDI was a decrease of DAA serum levels (11% of SOF/VEL and GLE/PIB patients) and an increased concentration of comedication serum levels (14% of SOF/VEL and 42% of GLE/PIB patients).

Conclusion: This real-world analysis provided a thorough characterization on the burden of polymedication regimens in HCV patients treated with SOF/VEL or GLE/PIB that expose such patients to an increased risk of DDIs. In our sample population, SOF/VEL regimen was more frequently detected on elderly patients and on those with ≥2 comedications at risk of multi-DDI, ie, among patients characterized by higher rates of comorbidities and polypharmacy.

目的:本研究旨在探讨多种药物和年龄对使用索非布韦/维帕他韦(SOF/VEL)或glecaprevir/pibrentasvir (GLE/PIB)治疗的HCV患者多重药物相互作用(ddi)发生率的影响。患者和方法:这是一项基于约690万人的行政数据的回顾性分析。纳入2017年11月至2020年3月期间接受SOF/VEL或GLE/PIB治疗的患者。与此期间的SOF/VEL或GLE/PIB首开处方对应的索引日期;随访患者治疗时间。然后将分析重点放在具有多重ddi风险的≥2种药物的患者。使用利物浦大学的工具确定多重DDI的严重程度和影响。结果:共入选SOF/VEL患者2057例,GLE/PIB患者2128例。SOF/VEL患者的平均年龄为58.5岁,高于GLE/PIB患者的平均年龄(52.5岁)(p < 0.001),并且>50岁的患者在SOF/VEL和GLE/PIB队列中更多:72%比58%,(p < 0.001)。大多数联合用药是心血管、消化和神经系统药物。使用≥2种药物的患者比例在SOF/VEL组高于GLE/PIB组(56.5% vs 32.3%, p < 0.001)。≥2种药物治疗的SOF/VEL患者中有11.6% (N = 135)存在多重ddi高危,GLE/PIB患者中有19.6% (N = 135)存在多重ddi高危(p < 0.001)。其中,DDI的潜在影响是降低血清DAA水平(占SOF/VEL和GLE/PIB患者的11%),增加血清药物浓度(占SOF/VEL的14%和GLE/PIB的42%)。结论:这一真实世界的分析提供了一个全面的特征,即在接受SOF/VEL或GLE/PIB治疗的HCV患者中,多重药物治疗方案的负担使这些患者的ddi风险增加。在我们的样本人群中,SOF/VEL方案在老年患者和使用≥2种药物有多重ddi风险的患者中更常见,即在合并症和多种药物发生率较高的患者中。
{"title":"Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).","authors":"Stefano Fagiuoli,&nbsp;Pierluigi Toniutto,&nbsp;Nicola Coppola,&nbsp;Domenica Daniela Ancona,&nbsp;Margherita Andretta,&nbsp;Fausto Bartolini,&nbsp;Fulvio Ferrante,&nbsp;Alessandro Lupi,&nbsp;Stefano Palcic,&nbsp;Francesca Vittoria Rizzi,&nbsp;Davide Re,&nbsp;Gema Alvarez Nieto,&nbsp;Candido Hernandez,&nbsp;Francesca Frigerio,&nbsp;Valentina Perrone,&nbsp;Luca Degli Esposti,&nbsp;Alessandra Mangia","doi":"10.2147/TCRM.S394467","DOIUrl":"https://doi.org/10.2147/TCRM.S394467","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims at investigating the impact of polymedication and aging in the prevalence of multiple drug-drug interactions (DDIs) on HCV patients treated with sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).</p><p><strong>Patients and methods: </strong>This is a retrospective analysis based on administrative data covering around 6.9 million individuals. Patients treated with SOF/VEL or GLE/PIB over November 2017-March 2020 were included. Index date corresponded to SOF/VEL or GLE/PIB first prescription during such period; patients were followed up for treatment duration. Analyses were then focused on patients with ≥2 comedications at risk of multiple DDIs. The severity and the effect of multiple DDI were identified using the Liverpool University tool.</p><p><strong>Results: </strong>A total of 2057 patients with SOF/VEL and 2128 with GLE/PIB were selected. Mean age of SOF/VEL patients was 58.5 years, higher than GLE/PIB ones (52.5 years) (p < 0.001), and patients >50 years were more present in SOF/VEL vs GLE/PIB cohorts: 72% vs 58%, (p < 0.001). Most prescribed co-medications were cardiovascular, alimentary and nervous system drugs. Proportion of patients with ≥2 comedications was higher in SOF/VEL compared to GLE/PIB cohort (56.5% vs 32.3%, p < 0.001). Those at high-risk of multiple DDIs accounted for 11.6% (N = 135) of SOF/VEL and 19.6% (N = 135) of GLE/PIB (p < 0.001) patients with ≥2 comedications. Among them, the potential effect of DDI was a decrease of DAA serum levels (11% of SOF/VEL and GLE/PIB patients) and an increased concentration of comedication serum levels (14% of SOF/VEL and 42% of GLE/PIB patients).</p><p><strong>Conclusion: </strong>This real-world analysis provided a thorough characterization on the burden of polymedication regimens in HCV patients treated with SOF/VEL or GLE/PIB that expose such patients to an increased risk of DDIs. In our sample population, SOF/VEL regimen was more frequently detected on elderly patients and on those with ≥2 comedications at risk of multi-DDI, ie, among patients characterized by higher rates of comorbidities and polypharmacy.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/87/tcrm-19-57.PMC9868280.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9177547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Changes in Anxiety and Depression After THA in Patients with Ankylosing Spondylitis and the Affecting Factors. 强直性脊柱炎患者THA术后焦虑、抑郁的变化及影响因素
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S415564
Hang Qian, Xu Wang, Pengbo Wang, Guangyang Zhang, Jun Liu, Xiaoqian Dang, Jianbin Guo, Ruiyu Liu

Objective: Hip ankylosis is a prevalent condition in patients with Ankylosing spondylitis (AS) that can significantly impact their psychological well-being. This study aimed to investigate the impact of Total Hip Arthroplasty (THA) on anxiety and depression among AS patients.

Methods: 62 AS patients undergoing primary THA were recruited and separated into two groups based on preoperative hip motion. The 40 patients with hip mobility of 0° were assigned to group A, and others were assigned to group NA. Self-rating Anxiety Scale (SAS), Self-rating Depression scale (SDS), Harris hip scores (HHS) and 36-Item Short Form Survey (SF-36) were obtained one week before and there, six and twelve months after THA.

Results: The study found that AS patients in group A had significantly higher levels of anxiety and depression (SAS score = 75.05±2.79, SDS index score = 0.74±0.02) compared to group B (SAS score = 54.58±3.35, SDS index score= 0.64±0.03, P=0.01). However, both groups showed significant improvements in anxiety and depression scores from there to twelve months after THA (P<0.001). Correlation analyses revealed that the improvement in group NA was associated with hip pain relief (p<0.001), while the improvement in group A was related to joint function, disease duration, age at THA and spine imaging lesions (p<0.001).

Conclusion: Some degree of anxiety and depression was present in both groups of AS patients. Levels of depression and anxiety were higher in patients with combined hip ankylosis. And their improvement was associated with improved hip function and quality of life after THA. Hip pain relief played a significant role in patients without hip joint ankylosis. The impact of the degree of lesion on spinal imaging on psychological status needs to be considered in both groups.

目的:髋关节强直性脊柱炎是强直性脊柱炎(AS)患者的一种常见疾病,可以显著影响他们的心理健康。本研究旨在探讨全髋关节置换术(THA)对AS患者焦虑和抑郁的影响。方法:选取62例行原发性全髋关节置换术的AS患者,根据术前髋关节运动情况分为两组。40例髋关节活动度为0°的患者分为A组,其余患者分为NA组。在THA前1周、THA后6个月、THA后12个月分别进行焦虑自评量表(SAS)、抑郁自评量表(SDS)、Harris髋关节评分(HHS)和36项简短问卷调查(SF-36)。结果:研究发现A组AS患者焦虑、抑郁水平(SAS评分= 75.05±2.79,SDS指数评分= 0.74±0.02)显著高于B组(SAS评分= 54.58±3.35,SDS指数评分= 0.64±0.03,P=0.01)。然而,两组患者在THA后12个月的焦虑和抑郁评分均有显著改善(结论:两组AS患者均存在一定程度的焦虑和抑郁。合并髋关节强直患者的抑郁和焦虑水平较高。他们的改善与髋关节功能的改善和THA后的生活质量有关。在无髋关节强直的患者中,髋关节疼痛缓解有显著作用。两组均需考虑脊柱影像学病变程度对心理状态的影响。
{"title":"Changes in Anxiety and Depression After THA in Patients with Ankylosing Spondylitis and the Affecting Factors.","authors":"Hang Qian,&nbsp;Xu Wang,&nbsp;Pengbo Wang,&nbsp;Guangyang Zhang,&nbsp;Jun Liu,&nbsp;Xiaoqian Dang,&nbsp;Jianbin Guo,&nbsp;Ruiyu Liu","doi":"10.2147/TCRM.S415564","DOIUrl":"https://doi.org/10.2147/TCRM.S415564","url":null,"abstract":"<p><strong>Objective: </strong>Hip ankylosis is a prevalent condition in patients with Ankylosing spondylitis (AS) that can significantly impact their psychological well-being. This study aimed to investigate the impact of Total Hip Arthroplasty (THA) on anxiety and depression among AS patients.</p><p><strong>Methods: </strong>62 AS patients undergoing primary THA were recruited and separated into two groups based on preoperative hip motion. The 40 patients with hip mobility of 0° were assigned to group A, and others were assigned to group NA. Self-rating Anxiety Scale (SAS), Self-rating Depression scale (SDS), Harris hip scores (HHS) and 36-Item Short Form Survey (SF-36) were obtained one week before and there, six and twelve months after THA.</p><p><strong>Results: </strong>The study found that AS patients in group A had significantly higher levels of anxiety and depression (SAS score = 75.05±2.79, SDS index score = 0.74±0.02) compared to group B (SAS score = 54.58±3.35, SDS index score= 0.64±0.03, P=0.01). However, both groups showed significant improvements in anxiety and depression scores from there to twelve months after THA (P<0.001). Correlation analyses revealed that the improvement in group NA was associated with hip pain relief (p<0.001), while the improvement in group A was related to joint function, disease duration, age at THA and spine imaging lesions (p<0.001).</p><p><strong>Conclusion: </strong>Some degree of anxiety and depression was present in both groups of AS patients. Levels of depression and anxiety were higher in patients with combined hip ankylosis. And their improvement was associated with improved hip function and quality of life after THA. Hip pain relief played a significant role in patients without hip joint ankylosis. The impact of the degree of lesion on spinal imaging on psychological status needs to be considered in both groups.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/49/tcrm-19-675.PMC10439721.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10048630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutics and Clinical Risk Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1